P8IP
MDGL icon

Pier 88 Investment Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pier 88 Investment Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698K Buy
1,300
+100
+8% +$51.2K 0.17% 42
2026
Q1 		$628K Buy
1,200
+120
+11% +$57.3K 0.16% 59
2025
Q4 		$629K Buy
+1,080
New +$552K 0.14% 74

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pier 88 Investment Partners's MDGL Position: Q2 2026 in Review

Pier 88 Investment Partners increased its Madrigal Pharmaceuticals (MDGL) stake by 8.3% in Q2 2026, buying an estimated $51.2K and bringing the position to 1,300 shares worth $698K. The position accounts for 0.17% of the portfolio, ranked #42.

Pier 88 Investment Partners first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Pier 88 Investment Partners held 1,300 shares of Madrigal Pharmaceuticals worth $698K as of Q2 2026.
  • Pier 88 Investment Partners bought 100 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $51.2K.
  • Madrigal Pharmaceuticals made up 0.17% of Pier 88 Investment Partners's portfolio in Q2 2026, its #42 holding.
  • Pier 88 Investment Partners first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Pier 88 Investment Partners's 13F filing for Q2 2026, filed 4 Aug 2026.